| An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor … LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ... Clinical cancer research 19 (1), 279-290, 2013 | 1003 | 2013 |
| Targeting Axl and Mer kinases in cancer A Verma, SL Warner, H Vankayalapati, DJ Bearss, S Sharma Molecular cancer therapeutics 10 (10), 1763-1773, 2011 | 262 | 2011 |
| Targeting Aurora-2 kinase in cancer SL Warner, DJ Bearss, H Han, DD Von Hoff Molecular cancer therapeutics 2 (6), 589-595, 2003 | 233 | 2003 |
| High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors V Sorna, ER Theisen, B Stephens, SL Warner, DJ Bearss, ... Journal of medicinal chemistry 56 (23), 9496-9508, 2013 | 203 | 2013 |
| S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth JC Chuang, SL Warner, D Vollmer, H Vankayalapati, S Redkar, ... Molecular cancer therapeutics 9 (5), 1443-1450, 2010 | 176 | 2010 |
| Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells SL Warner, BJ Stephens, S Nwokenkwo, G Hostetter, A Sugeng, ... Clinical Cancer Research 15 (21), 6519-6528, 2009 | 161 | 2009 |
| Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia IK Park, B Mundy-Bosse, SP Whitman, X Zhang, SL Warner, DJ Bearss, ... Leukemia 29 (12), 2382-2389, 2015 | 159 | 2015 |
| A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas JM Foulks, KJ Carpenter, B Luo, Y Xu, A Senina, R Nix, A Chan, A Clifford, ... Neoplasia 16 (5), 403-412, 2014 | 112 | 2014 |
| Design, synthesis, and biological evaluation of a series of novel AXL kinase inhibitors A Mollard, SL Warner, LT Call, ML Wade, JJ Bearss, A Verma, S Sharma, ... ACS medicinal chemistry letters 2 (12), 907-912, 2011 | 97 | 2011 |
| Activators of PKM2 in cancer metabolism SL Warner, KJ Carpenter, DJ Bearss Future medicinal chemistry 6 (10), 1167-1178, 2014 | 93 | 2014 |
| AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers K Balaji, S Vijayaraghavan, L Diao, P Tong, Y Fan, JPW Carey, TN Bui, ... Molecular Cancer Research 15 (1), 45-58, 2017 | 86 | 2017 |
| TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase X Wang, H Saso, T Iwamoto, W Xia, Y Gong, L Pusztai, WA Woodward, ... Cancer research 73 (21), 6516-6525, 2013 | 86 | 2013 |
| Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach SL Warner, S Bashyam, H Vankayalapati, DJ Bearss, H Han, DD Von Hoff, ... Molecular cancer therapeutics 5 (7), 1764-1773, 2006 | 86 | 2006 |
| Combined venetoclax and alvocidib in acute myeloid leukemia J Bogenberger, C Whatcott, N Hansen, D Delman, CX Shi, W Kim, ... Oncotarget 8 (63), 107206, 2017 | 76 | 2017 |
| Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors S Sinha, J Boysen, M Nelson, C Secreto, SL Warner, DJ Bearss, ... Clinical Cancer Research 21 (9), 2115-2126, 2015 | 73 | 2015 |
| Substituted tricyclic compounds as protein kinase inhibitors LH Hurley, D Mahadevan, DJ Bearss, H Vankayalapati, S Bashyam, ... US Patent 7,326,712, 2008 | 71* | 2008 |
| Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells SL Warner, RM Munoz, P Stafford, E Koller, LH Hurley, DD Von Hoff, ... Molecular cancer therapeutics 5 (10), 2450-2458, 2006 | 67 | 2006 |
| Protein Kinase Inhibitors LH Hurley, D Mahadevan, H Han, DJ Bearss, H Vankayalapati, ... US Patent App. 11/735,344, 2009 | 61 | 2009 |
| Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others SL Warner, PJ Gray, DD Von Hoff Seminars in oncology 33 (4), 436-448, 2006 | 56 | 2006 |
| Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase DJ Bearss, H Vankayalapati, A Mollard, SL Warner, S Sharma US Patent 8,901,120, 2014 | 49 | 2014 |
